Serum calprotectin is a biomarker of carotid atherosclerosis in patients with primary Sjögren's syndrome.

Abstract

pSS have a higher prevalence of carotid atherosclerosis, which is associated with higher serum calprotectin level independent of traditional cardiovascular risk factors. Our findings suggest calprotectin as a biomarker of subclinical atherosclerosis in pSS.